Experimental/Emerging Composite Scores
Multi-modality algorithms pairing elastography imaging with blood biomarkers and clinical factors to narrow indeterminate zones.
When a blood test says one thing and an imaging scan lands in a borderline gray zone, combining both into a single composite score shrinks the uncertainty. FAST, Agile 3+, and Agile 4 combine your FibroScan numbers with routine labs like AST, ALT, platelets, and diabetes status right inside clinic apps, while MEFIB and MAST pair MRI scans with blood work to pinpoint 'at-risk' MASH (active inflammation plus stage F2 or higher scarring) without needing a biopsy.
Emerging Composite Tools for Noninvasive Fibrosis Assessment in MASLD1-3
| Subtest | Parameters Involved | Applications | Cutoff | Sensitivity, %a | Specificity, %b |
|---|---|---|---|---|---|
| MEFIB1,4 | MRE + FIB-4 score | Identifies MASHc and ≥F2 | Rule in: MRE: ≥3.3 kPa plus FIB-4: ≥1.6 |
NR | NR |
| MAST2,4 | MRI-PDFF, MRE, and AST | Identifies MASHc and ≥F2 | Rule out: ≤0.165 | 72.2 | 89.3 |
| Rule in: ≥0.242 | 90.3 | 75.0 | |||
| FAST5,d | LSM by VCTE™, CAP™ + AST | Identifies MASHc and ≥F2 | Rule out: ≤0.35 | 89.0 | 64.0 |
| Rule in: ≥0.67 | 49.0 | 92.0 | |||
| Agile 3+6,d | LSM by VCTE™ + AST + ALT + platelets + diabetes status + sex + age | Identifies ≥F3 in patients with MASLD | Rule out: <0.451 | 82.0 | 75.0 |
| Rule in: ≥0.679 | 61.0 | 87.0 | |||
| Agile 46,d | LSM by VCTE™ + AST + ALT + platelets + diabetes status + sex | Identifies F4 in patients with MASLD | Rule out: <0.251 | 87.0 | 86.0 |
| Rule in: ≥0.565 | 55.0 | 97.0 |